{
    "clinical_study": {
        "@rank": "100698", 
        "arm_group": [
            {
                "arm_group_label": "continued tacrolimus treatment", 
                "arm_group_type": "Experimental", 
                "description": "children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period."
            }, 
            {
                "arm_group_label": "no additional treatment", 
                "arm_group_type": "No Intervention", 
                "description": "children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period."
            }
        ], 
        "brief_summary": {
            "textblock": "To assess if proactive, 2 times-weekly application of tacrolimus ointment can extend\n      remission time to relapse and reduce the incidence of disease exacerbation (DE) in\n      paediatric patients over a period of 6 months."
        }, 
        "brief_title": "Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Moderate/Severe Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study includes three periods.  First a screening period of up to one week.  Second an\n      open-label treatment period of up to six weeks where all participants apply tacrolimus\n      ointment. Third an open-label disease control period of up to six months where half of the\n      participants apply tacrolimus ointment and the other half of the participants do not apply\n      treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Diagnosed as AD according to Williams diagnostic criteria.\n\n          2. Moderate or severe atopic dermatitis according to the criteria of Rajka and Langeland\n\n          3. At least approximately 10 % of body area\n\n          4. Patient is able to reach the centre within 3 days in case of a disease exacerbation.\n\n          5. Patient`s legal representative(s) has/have given written informed consent. If the\n             patient is capable of understanding the purposes and risks of the trial, written\n             informed consent has been obtained from the patient as well"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745159", 
            "org_study_id": "ACN-PRT-AD-12-1"
        }, 
        "intervention": {
            "arm_group_label": "continued tacrolimus treatment", 
            "intervention_name": "tacrolimus", 
            "intervention_type": "Drug", 
            "other_name": "Protopic"
        }, 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "tacrolimus", 
            "Protopic", 
            "pediatric", 
            "atopic dermatitis", 
            "China"
        ], 
        "lastchanged_date": "December 6, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chongqing", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study", 
        "overall_contact": {
            "email": "clinical_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first DE (disease exacerbation)", 
            "safety_issue": "No", 
            "time_frame": "6 months of DCP(Disease Control Period) after 2 to 6 weeks of OLP(Open Label Period)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of DEs during the DCP", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period)"
            }, 
            {
                "measure": "Eczema Area and Severity Index (EASI)", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)"
            }, 
            {
                "measure": "Investigator`s Global Assessment (IGA)", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)"
            }, 
            {
                "measure": "Duration of DE during DCP", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period)"
            }, 
            {
                "measure": "The overall efficacy during OLP", 
                "safety_issue": "No", 
                "time_frame": "After 2 to 6 weeks of OLP (Open Label Period)"
            }, 
            {
                "measure": "Quantity of tacrolimus ointment used", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma China, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}